| Paroxysmal nocturnal hemoglobinuria
Bkemv vs Empaveli
Side-by-side clinical, coverage, and cost comparison for paroxysmal nocturnal hemoglobinuria.Deep comparison between: Bkemv vs Empaveli with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEmpaveli has a higher rate of injection site reactions vs Bkemv based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Empaveli but not Bkemv, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Bkemv
Empaveli
At A Glance
IV infusion
Every 2 weeks
Complement C5 inhibitor
SC injection
Twice weekly
C3 complement inhibitor
Indications
- Paroxysmal nocturnal hemoglobinuria
- Atypical Hemolytic Uremic Syndrome
- Myasthenia Gravis, Generalized
- Paroxysmal nocturnal hemoglobinuria
- C3 glomerulopathy
- Immune-complex membranoproliferative glomerulonephritis
Dosing
Paroxysmal nocturnal hemoglobinuria 600 mg IV weekly for 4 weeks, then 900 mg at week 5, then 900 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized 900 mg IV weekly for 4 weeks, then 1,200 mg at week 5, then 1,200 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome (pediatric, <18 years) Weight-based IV dosing: induction 300-900 mg and maintenance 300-1,200 mg every 2-3 weeks depending on body weight (5 kg and over).
Paroxysmal nocturnal hemoglobinuria 1,080 mg SC twice weekly; adjust to 1,080 mg every three days if LDH >2x ULN.
C3 glomerulopathy, Immune-complex membranoproliferative glomerulonephritis Adults: 1,080 mg SC twice weekly; pediatric patients (12 to <18 years): weight-based dosing from 648 mg to 1,080 mg SC twice weekly based on body weight.
Contraindications
- Unresolved serious Neisseria meningitidis infection
- Hypersensitivity to pegcetacoplan or any excipient
- Unresolved serious infection caused by encapsulated bacteria including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B
Adverse Reactions
Most common (>=5%) Headache, nasopharyngitis, back pain, nausea, fatigue, cough, herpes simplex infections, musculoskeletal pain, hypertension, diarrhea, vomiting, pyrexia, peripheral edema.
Serious Meningococcal infections, other serious infections, thrombosis, infusion-related reactions, disease manifestation exacerbation after discontinuation.
Postmarketing Fatal or serious infections (Neisseria gonorrhoeae, Neisseria meningitidis, Neisseria species), cholestatic or mixed pattern liver injury with elevated liver enzymes and bilirubin.
Most common (>=10%) Injection-site reactions, infections, diarrhea, abdominal pain, respiratory tract infection, viral infection, fatigue
Serious Infections, intestinal ischemia, biliary sepsis, hypersensitivity pneumonitis
Postmarketing Anaphylaxis, urticaria
Pharmacology
Complement C5 inhibitor; eculizumab-aeeb is a recombinant humanized monoclonal IgG2/4kappa antibody that specifically binds complement protein C5 with high affinity, inhibiting its cleavage to C5a and C5b and preventing generation of the terminal complement complex C5b-9, thereby inhibiting terminal complement-mediated intravascular hemolysis in PNH and complement-mediated thrombotic microangiopathy in aHUS.
C3 complement inhibitor; pegcetacoplan binds complement protein C3 and its activation fragment C3b, regulating downstream complement activation to control both C3b-mediated extravascular hemolysis and terminal complement-mediated intravascular hemolysis in PNH, and to inhibit C3 glomerular fragment deposition and C5b-9 assembly in C3G and primary IC-MPGN.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bkemv
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
Empaveli
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Bkemv
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Empaveli
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Bkemv
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Empaveli
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Bkemv.
Cost estimate not availableApellis Bridge Program: Empaveli
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EmpaveliView full Empaveli profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.